Finanzen von Apimeds Pharmaceuticals US Inc (APUS)APUSApimeds Pharmaceuticals US Inc

Evaluating the bottom line, Apimeds Pharmaceuticals US Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -100.13%, provide a clear picture of how effectively APUS converts its operational activities into shareholder value.

In the context of the broader market, APUS competes directly with industry leaders such as GRI and NCNA. With a market capitalization of $4.05M, it holds a significant position in the sector. When comparing efficiency, APUS's gross margin of N/A stands against GRI's N/A and NCNA's N/A. Such benchmarking helps identify whether Apimeds Pharmaceuticals US Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with losses increasing significantly in recent quarters, such as a loss of $35,059,852 in Q1 2026. The gross profit has also been negative, indicating poor operational performance.